Inventiva (NASDAQ:IVA) Stock Rating Upgraded by Truist Financial

Inventiva (NASDAQ:IVA) was upgraded by Truist Financial to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Several other equities research analysts have also weighed in on IVA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. HC Wainwright set a $24.00 price target on shares of Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. Guggenheim decreased their price objective on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Leerink Partners assumed coverage on shares of Inventiva in a report on Monday, January 12th. They set an “outperform” rating and a $12.00 price objective for the company. Finally, UBS Group initiated coverage on shares of Inventiva in a research note on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Trading Up 1.3%

Shares of NASDAQ:IVA opened at $6.04 on Wednesday. The business’s fifty day moving average price is $6.28 and its two-hundred day moving average price is $5.36. Inventiva has a fifty-two week low of $2.70 and a fifty-two week high of $7.98.

Institutional Trading of Inventiva

Several hedge funds have recently modified their holdings of IVA. Creative Planning acquired a new stake in shares of Inventiva in the second quarter valued at approximately $32,000. Virtu Financial LLC acquired a new position in Inventiva during the 4th quarter worth $60,000. XTX Topco Ltd bought a new position in Inventiva in the 4th quarter valued at $84,000. Cerity Partners LLC acquired a new stake in shares of Inventiva in the 4th quarter valued at $93,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the 3rd quarter valued at $116,000. 19.06% of the stock is owned by institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.